southeast Asian ovalocytosis
disease diseaseOn this page
Also known as hereditary ovalocytosisMelanesian elliptocytosisMelanesian ovalocytosisovalocytosis, SA typeSAOstomatocytic elliptocytosis
Summary
southeast Asian ovalocytosis (MONDO:0008165) is a disease caused by SLC4A1 (GenCC Strong), with 1 cohort gene.
At a glance
- Prevalence: <1 / 1 000 000 (Europe)
- Causal gene: SLC4A1 (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 156
- Phenotypes (HPO): 16
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | <1 / 1 000 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
16 HPO clinical features (Orphanet curated; top 16 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000952 | Jaundice | Frequent (30-79%) |
| HP:0001017 | Anemic pallor | Frequent (30-79%) |
| HP:0001744 | Splenomegaly | Frequent (30-79%) |
| HP:0001878 | Hemolytic anemia | Frequent (30-79%) |
| HP:0001923 | Reticulocytosis | Frequent (30-79%) |
| HP:0003546 | Exercise intolerance | Frequent (30-79%) |
| HP:0004445 | Elliptocytosis | Frequent (30-79%) |
| HP:0004446 | Stomatocytosis | Frequent (30-79%) |
| HP:0008282 | Unconjugated hyperbilirubinemia | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0020181 | Reduced haptoglobin level | Frequent (30-79%) |
| HP:0025435 | Increased circulating lactate dehydrogenase concentration | Frequent (30-79%) |
| HP:0034609 | Polychromasia | Frequent (30-79%) |
| HP:0001947 | Renal tubular acidosis | Occasional (5-29%) |
| HP:0004444 | Spherocytosis | Occasional (5-29%) |
| HP:0005518 | Increased mean corpuscular volume | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | southeast Asian ovalocytosis |
| Mondo ID | MONDO:0008165 |
| OMIM | 166900 |
| Orphanet | 98868 |
| ICD-11 | 835618545 |
| SNOMED CT | 191169008 |
| UMLS | C1862322 |
| MedGen | 350649 |
| GARD | 0016867 |
| Is cancer (heuristic) | no |
Also known as: hereditary ovalocytosis · Melanesian elliptocytosis · Melanesian ovalocytosis · ovalocytosis, SA type · SAO · sao · stomatocytic elliptocytosis
Data availability: 156 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › normocytic anemia › hemolytic anemia › familial hemolytic anemia › southeast Asian ovalocytosis
Related subtypes (22): congenital nonspherocytic hemolytic anemia, elliptocytosis 2, overhydrated hereditary stomatocytosis, cryohydrocytosis, dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, abetalipoproteinemia, hemolytic anemia due to diphosphoglycerate mutase deficiency, glycogen storage disease VII, cutaneous porphyria, hereditary cryohydrocytosis with reduced stomatin, familial pseudohyperkalemia, renal tubular acidosis, distal, 4, with hemolytic anemia, elliptocytosis 1, glycogen storage disease due to aldolase A deficiency, primary CD59 deficiency, triosephosphate isomerase deficiency, dehydrated hereditary stomatocytosis 2, Rh deficiency syndrome, hereditary spherocytosis, congenital dyserythropoietic anemia, X-linked congenital hemolytic anemia, hemolytic disease of fetus and newborn, RH-induced
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
156 retrieved; paginated sample, class counts are floors:
99 uncertain significance, 24 conflicting classifications of pathogenicity, 10 pathogenic/likely pathogenic, 9 benign/likely benign, 7 likely benign, 4 likely pathogenic, 3 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 17753 | NM_000342.4(SLC4A1):c.1199_1225del (p.Ala400_Ala408del) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 17762 | NM_000342.3(SLC4A1):c.448C>T (p.Arg150Ter) | SLC4A1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 17763 | NM_000342.4(SLC4A1):c.1766G>A (p.Arg589His) | SLC4A1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 17764 | NM_000342.4(SLC4A1):c.1765C>T (p.Arg589Cys) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 17767 | NM_000342.4(SLC4A1):c.2102G>A (p.Gly701Asp) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 17771 | NM_000342.4(SLC4A1):c.2573C>A (p.Ala858Asp) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 17773 | NM_000342.3(SLC4A1):c.1462G>A (p.Val488Met) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 17780 | NM_000342.3(SLC4A1):c.2279G>A (p.Arg760Gln) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 235293 | NM_000342.4(SLC4A1):c.1825G>A (p.Gly609Arg) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3382897 | NM_000342.4(SLC4A1):c.2020del (p.Val674fs) | SLC4A1 | Pathogenic | criteria provided, single submitter |
| 3582115 | NM_000342.4(SLC4A1):c.1242del (p.Phe414fs) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 620131 | NM_000342.4(SLC4A1):c.1030C>T (p.Arg344Ter) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 971626 | NM_000342.4(SLC4A1):c.2726T>C (p.Met909Thr) | SLC4A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3780627 | NC_000002.12:g.42108272_42108298del | Likely pathogenic | criteria provided, single submitter | |
| 1163104 | NM_000342.4(SLC4A1):c.2260C>T (p.Gln754Ter) | SLC4A1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1275803 | NM_000342.4(SLC4A1):c.2716G>T (p.Glu906Ter) | SLC4A1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2433471 | NM_000342.4(SLC4A1):c.349+1G>C | SLC4A1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1008971 | NM_000342.4(SLC4A1):c.1181T>C (p.Leu394Pro) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1044950 | NM_000342.4(SLC4A1):c.1160G>A (p.Arg387Gln) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1050262 | NM_000342.4(SLC4A1):c.538C>T (p.Arg180Cys) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1162821 | NM_000342.4(SLC4A1):c.277G>T (p.Ala93Ser) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1343087 | NM_000342.4(SLC4A1):c.2656C>A (p.Leu886Met) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1420205 | NM_000342.4(SLC4A1):c.2344C>T (p.Arg782Cys) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1495044 | NM_000342.4(SLC4A1):c.523C>A (p.Pro175Thr) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1676955 | NM_000342.4(SLC4A1):c.2116C>A (p.Leu706Met) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 17759 | NM_000342.4(SLC4A1):c.1972G>A (p.Glu658Lys) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 17769 | NM_000342.3(SLC4A1):c.388G>A (p.Gly130Arg) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 17775 | NM_000342.3(SLC4A1):c.268G>A (p.Glu90Lys) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1911618 | NM_000342.4(SLC4A1):c.82G>A (p.Glu28Lys) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2044789 | NM_000342.4(SLC4A1):c.1442C>G (p.Thr481Ser) | SLC4A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 15 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| SLC4A1 | Strong | Autosomal dominant | southeast Asian ovalocytosis | 15 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| SLC4A1 | Orphanet:3202 | Dehydrated hereditary stomatocytosis |
| SLC4A1 | Orphanet:398088 | Hereditary cryohydrocytosis with normal stomatin |
| SLC4A1 | Orphanet:822 | Hereditary spherocytosis |
| SLC4A1 | Orphanet:93608 | Autosomal dominant distal renal tubular acidosis |
| SLC4A1 | Orphanet:93610 | Distal renal tubular acidosis with anemia |
| SLC4A1 | Orphanet:98868 | Southeast Asian ovalocytosis |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| SLC4A1 | HGNC:11027 | ENSG00000004939 | P02730 | Band 3 anion transport protein | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| SLC4A1 | Band 3 anion transport protein | Functions both as a transporter that mediates electroneutral anion exchange across the cell membrane and as a structural protein. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| SLC4A1 | Other/Unknown | no | Anion_exchange, Anion_exchange_1, HCO3_transpt_euk |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| bone marrow | 1 |
| bone marrow cell | 1 |
| trabecular bone tissue | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| SLC4A1 | 161 | tissue_specific | marker | trabecular bone tissue, bone marrow, bone marrow cell |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| SLC4A1 | 1,598 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| SLC4A1 | P02730 | 54 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 11. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | 1 | 11420.0× | 1e-03 | SLC4A1 |
| Erythrocytes take up oxygen and release carbon dioxide | 1 | 1268.9× | 0.002 | SLC4A1 |
| O2/CO2 exchange in erythrocytes | 1 | 1268.9× | 0.002 | SLC4A1 |
| Bicarbonate transporters | 1 | 1142.0× | 0.002 | SLC4A1 |
| Erythrocytes take up carbon dioxide and release oxygen | 1 | 878.5× | 0.003 | SLC4A1 |
| SLC transporter disorders | 1 | 203.9× | 0.009 | SLC4A1 |
| Disorders of transmembrane transporters | 1 | 139.3× | 0.011 | SLC4A1 |
| R-HSA-425393 | 1 | 129.8× | 0.011 | SLC4A1 |
| SLC-mediated transmembrane transport | 1 | 59.2× | 0.021 | SLC4A1 |
| Transport of small molecules | 1 | 25.1× | 0.044 | SLC4A1 |
| Disease | 1 | 13.1× | 0.076 | SLC4A1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| response to increased oxygen levels | 1 | 16852.0× | 4e-04 | SLC4A1 |
| pH elevation | 1 | 16852.0× | 4e-04 | SLC4A1 |
| intracellular monoatomic ion homeostasis | 1 | 4213.0× | 9e-04 | SLC4A1 |
| negative regulation of urine volume | 1 | 4213.0× | 9e-04 | SLC4A1 |
| negative regulation of glycolytic process through fructose-6-phosphate | 1 | 2808.7× | 0.001 | SLC4A1 |
| plasma membrane phospholipid scrambling | 1 | 1532.0× | 0.002 | SLC4A1 |
| monoatomic anion transport | 1 | 1404.3× | 0.002 | SLC4A1 |
| bicarbonate transport | 1 | 802.5× | 0.002 | SLC4A1 |
| regulation of intracellular pH | 1 | 601.9× | 0.003 | SLC4A1 |
| erythrocyte development | 1 | 526.6× | 0.003 | SLC4A1 |
| chloride transport | 1 | 455.5× | 0.003 | SLC4A1 |
| chloride transmembrane transport | 1 | 237.3× | 0.005 | SLC4A1 |
| blood coagulation | 1 | 173.7× | 0.006 | SLC4A1 |
| transmembrane transport | 1 | 168.5× | 0.006 | SLC4A1 |
| protein localization to plasma membrane | 1 | 108.7× | 0.009 | SLC4A1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| SLC4A1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | SLC4A1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| SLC4A1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: SLC4A1